Getting a tattoo can be a thrilling, albeit painful, experience. About one-third of Australians have a tattoo, with many ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Roughly 55 percent of Medicaid enrollees are working full or part time, and a number aren’t eligible for health insurance ...

AI-powered wearable glasses empower individuals living with age-related macular degeneration (AMD) and other retinal ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

Darrell E. White, MD, is the founder of Skyvision Centers in Ohio. His blog for Ocular Surgery News will focus on issues related to dry eye disease.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

Two very special animals received sight-saving care in Southern Oregon through a unique partnership between a local ...

A University of Wisconsin School of Veterinary Medicine researcher is studying blacklegged ticks with an eye toward improving ...

METHODOLOGY: Researchers conducted a retrospective review of charts to evaluate the changes in health conditions or ...